
Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure
Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen.
Originally published on 30/05/2017
Imcyse will run its first clinical trial testing a specific immunotherapy that could finally provide a cure to autoimmune diseases.
Imcyse, a Belgian biotech spun out from the Katholieke Universiteit Leuven in 2010, just announced it has received approval from Belgian and British regulatory authorities to launch a Phase Ib trial in patients with type 1 diabetes. The study is backed with funding from the EU through the EXALT program, which has a budget of €6M over 5 years to promote the development of a cure for type 1 diabetes.
The trial, run in collaboration with the French Inserm, will be run in 18 sites across Belgium, Denmark, France, Germany, and the UK. It will be the first study in humans testing Imcyse’s immunotherapy technology, which is aimed at stopping the destruction of insulin-producing beta pancreatic cells in patients diagnosed with the disease within 6 months before the trial, when not all beta cells have yet been eliminated. Results are expected at the end of 2018.
Imcyse develops Imotopes, modified peptides that induce cytolytic CD4 T cells to kill other immune cells involved in the destruction of a specific target, in this case insulin-producing cells, without affecting any other functions of the immune system. The peptides are composed of an e
Continue
reading